Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.
Location: United States, California, Redwood City
Employees: 1-10
Total raised: $208M
Investors 2
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| 11.07.2025 | B Capital ... | bcapgroup.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.12.2024 | Series B | $161M | B Capital ... |
| 12.05.2022 | Series A | $47M | Novo Holdi... |
Mentions in press and media 6
| Date | Title | Description |
| 08.12.2024 | Nuvig: $161 Million (Series B) Raised To Develop Novel Immunomodulatory Therapeutics | Nuvig Therapeutics – a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases – announced the closing of a $161 million Series B round. The funding was co-led b... |
| 05.12.2024 | Sanofi-backed Nuvig marches lead autoimmune therapy into phase 2 with $161M series B | Big Pharma-backed immunomodulation biotech Nuvig Therapeutics is moving its lead asset into phase 2 trials using a $161 million war chest. The series B fundraising round was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities and N... |
| 05.12.2024 | Nuvig Therapeutics Raises $161M in Series B Funding | Nuvig Therapeutics, a Menlo Park, CA-based privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, raised $161M in Series B funding. The round was led by Sanofi... |
| 14.08.2024 | Enabling Clinical Programs Through Antibody Glycosylation, Upcoming Webinar Hosted by Xtalks | www.atum.bio In this free webinar, learn about antibody N- or O-linked glycosylation detection and engineering the identity and abundance of glycans during antibody manufacturing. Attendees will be introduced to functional examples on how g... |
| 12.05.2022 | Nuvig Therapeutics Closes $47M Series A Financing | Nuvig Therapeutics, a Redwood City, CA-based developer of therapies that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function, raised $47M in Series A funding. The round was led b... |
| - | Nuvig Therapeutics | “Our mission is to bring innovative and transformational therapies to patients with chronic autoimmune disease, via induction of mechanisms that restore immune homeostasis.” |